Patrycja Gradowska
YOU?
Author Swipe
View article: Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial Open
View article: A revised prognostic model for patients with acute myeloid leukemia and first relapse
A revised prognostic model for patients with acute myeloid leukemia and first relapse Open
Most patients with acute myeloid leukemia (AML) may obtain remission upon induction chemotherapy, but relapse is frequent and associated with poor survival. Previous prognostic models for outcomes after relapse lacked analysis of comprehen…
View article: Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients Open
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognosti…
View article: Heart Failure in Patients with Acute Myeloid Leukemia (AML) Treated with Anthracycline Agents During Remission Induction Therapy: A Systematic Review and Meta-Analysis
Heart Failure in Patients with Acute Myeloid Leukemia (AML) Treated with Anthracycline Agents During Remission Induction Therapy: A Systematic Review and Meta-Analysis Open
Patients with acute myeloid leukemia (AML) are at high risk of cardiovascular disease, particularly heart failure. Anthracyclines are integral to remission induction in patients eligible for intensive treatment and well-known for their ass…
View article: A data management system for precision medicine
A data management system for precision medicine Open
Precision, or personalised medicine has advanced requirements for medical data management systems (MedDMSs). MedDMS for precision medicine should be able to process hundreds of parameters from multiple sites, be adaptable while remaining i…
View article: Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models
Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models Open
View article: Risk Stratification in Older Intensively Treated Patients With AML
Risk Stratification in Older Intensively Treated Patients With AML Open
PURPOSE AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive chemotherapy followed by allogeneic hema…
View article: The role of the primitive marker <scp>CD133</scp> in <scp>CD34</scp>‐negative acute myeloid leukemia for the detection of leukemia stem cells
The role of the primitive marker <span>CD133</span> in <span>CD34</span>‐negative acute myeloid leukemia for the detection of leukemia stem cells Open
The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. I…
View article: Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial Open
View article: A data management system for precision medicine
A data management system for precision medicine Open
Introduction Precision, or personalised medicine has advanced requirements for medical data management systems (MedDMSs). MedDMS for precision medicine should be able to process hundreds of parameters from multiple sites, be adaptable whil…
View article: P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY. Open
Background: Measurable residual disease (MRD) is currently implemented to guide consolidation treatment in intermediate-risk AML. Optimization of MRD results is therefore crucial for clinical decision making. MRD can be detected by multipa…
View article: Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival Open
Not available.
View article: Figure S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Biological replicates of ChIP-seq analyses for ERalpha (A), RNA Polymerase II (B), H3K27Ac (C) and FOXA1 (D).
View article: Table S6 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S6 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
ChIP-seq read count and mapped reads of endometrial tumors.
View article: Figure S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Validation of two FOXA1 antibodies that were used for either ChIP or immunohistochemistry.
View article: Table S4 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S4 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Accession numbers of Ishikawa RNA-seq and ChIP-seq datasets generated by the ENCODE consortium and publicly available ERalpha ChIP-seq data from breast tumors.
View article: Figure S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Validation of two FOXA1 antibodies that were used for either ChIP or immunohistochemistry.
View article: Figure S5 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S5 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
RT-PCR analysis of 20 transcription factors in four tamoxifen-associated endometrial tumors and Ishikawa cells. Corresponding primers can be found in supplementary table S6.
View article: Figure S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Biological replicates of ChIP-seq analyses for ERalpha (A), RNA Polymerase II (B), H3K27Ac (C) and FOXA1 (D).
View article: Table S4 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S4 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Accession numbers of Ishikawa RNA-seq and ChIP-seq datasets generated by the ENCODE consortium and publicly available ERalpha ChIP-seq data from breast tumors.
View article: Figure S8 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S8 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Kaplan-Meier survival plot of endometrial cancer patients who were not treated with tamoxifen for their breast cancer, categorized as ERalpha+/FOXA1+, ERalpha+/FOXA1-, ERalpha-/FOXA1+ or ERalpha-/FOXA1-.
View article: Table S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S3 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Primer sequences corresponding with supplemental figure S2, to validate ChIP-seq on qPCR.
View article: Table S8 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S8 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Ingenuity Pathway Analysis on genes with ERalpha, FOXA1 or both in the gene body or within 20 kb upstream from the Transcriptional Start Site.
View article: Table S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Clinicopathological parameters of patient samples in the TAMARISK-study. MC-UC = interval between breast cancer and endometrial cancer.
View article: supplementary figure and table legends from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
supplementary figure and table legends from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
legends to supplementary tables and figures
View article: Figure S6 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Figure S6 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
2D graph, showing normalized read count of the shared binding sites for ERalpha and FOXA1 (blue), ERalpha only (red) and FOXA1 only (green) in ChIP-seq datasets of all indicated transcriptional regulators in the endometrial cancer cell lin…
View article: supplementary figure and table legends from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
supplementary figure and table legends from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
legends to supplementary tables and figures
View article: Data from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Data from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Tamoxifen, a small-molecule antagonist of the transcription factor estrogen receptor alpha (ERα) used to treat breast cancer, increases risks of endometrial cancer. However, no parallels of ERα transcriptional action in breast and endometr…
View article: supplementary methods from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
supplementary methods from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
supplementary methods
View article: Table S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas
Table S1 from Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Open
Clinicopathological parameters of patient samples in the TAMARISK-study. MC-UC = interval between breast cancer and endometrial cancer.